Literature DB >> 2496281

Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up--a comparison.

L Mattsson1, O Weiland, H Glaumann.   

Abstract

Ninety-two patients with biopsy-proven chronic non-A, non-B hepatitis after blood transfusions, illicit self-injections or sporadically were followed clinically for an average of nearly 5 years. In the posttransfusion hepatitis group, which comprised 37 patients with a mean age of 54 years (range 18-83 years), 59% developed chronic active hepatitis (CAH) and 46% also showed signs of early cirrhosis (eCi) or manifest cirrhosis (Ci). In the illicit self-injection group, comprising 33 patients with a mean age of 26 years (range 17-63 years), 39% manifested CAH and 18% eCi or Ci. In the sporadic group, which consisted of 22 patients with a mean age of 32 years (range 16-62 years), 41% showed CAH and 23% eCi. Thus, in all, 44/92 (48%) of the patients with chronic non-A, non-B hepatitis developed CAH and 28/92 (30%) signs of early or manifest cirrhosis. Patients greater than or equal to 30 years of age displayed CAH and signs of cirrhosis more often than patients less than 30 years of age (p less than 0.01). Chronic non-A, non-B hepatitis is a slowly progressive disease with a high incidence of cirrhosis, especially in patients greater than or equal to 30 years of age and when caused by blood transfusion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496281     DOI: 10.1111/j.1600-0676.1989.tb00388.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  13 in total

1.  Clinical sequelae of hepatitis C acquired from injection drug use.

Authors:  M J Tong; N S el-Farra
Journal:  West J Med       Date:  1996-05

2.  Hepatitis C virus--a pathogen for all people.

Authors:  L Dove; T L Wright
Journal:  West J Med       Date:  1996-06

Review 3.  Patterns of progression: unpredictability and risk of decompensated cirrhosis.

Authors:  N C Tassopoulos
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 4.  Risks and benefits of interferon-alpha in the treatment of hepatitis.

Authors:  M Pardo; E Marriott; M C Moliner; J A Quiroga; V Carreño
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

5.  Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.

Authors:  K Stein; W Rosenberg; J Wong
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

6.  Incidence, prevalence, and clinical course of hepatitis C following liver transplantation.

Authors:  G Shah; A J Demetris; J S Gavaler; J H Lewis; S Todo; T E Starzl; D H Van Thiel
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

7.  Chronic non-A, non-B hepatitis: role of hepatitis C virus.

Authors:  R Iorio; S Guida; S Porzio; I Fariello; A Vegnente
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

8.  Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.

Authors:  R Wejstål; G Norkrans; O Weiland; R Schvarcz; D Fuchs; H Wachter; A Fryden; H Glaumann
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 9.  Viral markers in the treatment of hepatitis B and C.

Authors:  H Schmilovitz-Weiss; M Levy; N Thompson; G Dusheiko
Journal:  Gut       Date:  1993       Impact factor: 23.059

10.  Hepatitis C-virus (HCV) antibodies in patients after kidney transplantation.

Authors:  P Baur; V Daniel; S Pomer; H Scheurlen; G Opelz; D Roelcke
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.